JP2012533558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533558A5 JP2012533558A5 JP2012520789A JP2012520789A JP2012533558A5 JP 2012533558 A5 JP2012533558 A5 JP 2012533558A5 JP 2012520789 A JP2012520789 A JP 2012520789A JP 2012520789 A JP2012520789 A JP 2012520789A JP 2012533558 A5 JP2012533558 A5 JP 2012533558A5
- Authority
- JP
- Japan
- Prior art keywords
- rsv
- protein
- seq
- polypeptide
- ectodomain polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 200
- 229920001184 polypeptide Polymers 0.000 claims description 180
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 180
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 139
- 238000000034 method Methods 0.000 claims description 92
- 239000000203 mixture Substances 0.000 claims description 78
- 210000004027 cell Anatomy 0.000 claims description 62
- 239000003636 conditioned culture medium Substances 0.000 claims description 62
- 239000013638 trimer Substances 0.000 claims description 56
- 239000000178 monomer Substances 0.000 claims description 44
- 239000013592 cell lysate Substances 0.000 claims description 40
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 230000002163 immunogen Effects 0.000 claims description 32
- 239000012620 biological material Substances 0.000 claims description 24
- 238000003776 cleavage reaction Methods 0.000 claims description 23
- 230000007017 scission Effects 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 102000004961 Furin Human genes 0.000 claims description 16
- 108090001126 Furin Proteins 0.000 claims description 16
- 241000238631 Hexapoda Species 0.000 claims description 16
- 230000004927 fusion Effects 0.000 claims description 16
- 210000004962 mammalian cell Anatomy 0.000 claims description 16
- 241000271566 Aves Species 0.000 claims description 14
- 241000223892 Tetrahymena Species 0.000 claims description 14
- 210000005253 yeast cell Anatomy 0.000 claims description 14
- 102000004895 Lipoproteins Human genes 0.000 claims description 12
- 108090001030 Lipoproteins Proteins 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 102000035195 Peptidases Human genes 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 239000004365 Protease Substances 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 238000005829 trimerization reaction Methods 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 238000006384 oligomerization reaction Methods 0.000 claims description 4
- -1 benzonaphthyridine compound Chemical class 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 108091000126 Dihydroorotase Proteins 0.000 claims description 2
- 108010074860 Factor Xa Proteins 0.000 claims description 2
- 101710154606 Hemagglutinin Proteins 0.000 claims description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 2
- 101710176177 Protein A56 Proteins 0.000 claims description 2
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 claims description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000185 hemagglutinin Substances 0.000 claims description 2
- 230000000091 immunopotentiator Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- BJVCSICIEDHBNI-UHFFFAOYSA-N benzo[b][1,8]naphthyridine Chemical class N1=CC=CC2=CC3=CC=CC=C3N=C21 BJVCSICIEDHBNI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22580509P | 2009-07-15 | 2009-07-15 | |
| US61/225,805 | 2009-07-15 | ||
| US29442610P | 2010-01-12 | 2010-01-12 | |
| US61/294,426 | 2010-01-12 | ||
| PCT/US2010/042161 WO2011008974A2 (en) | 2009-07-15 | 2010-07-15 | Rsv f protein compositions and methods for making same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095502A Division JP2015145422A (ja) | 2009-07-15 | 2015-05-08 | Ｒｓｖｆタンパク質組成物およびそれを作製するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012533558A JP2012533558A (ja) | 2012-12-27 |
| JP2012533558A5 true JP2012533558A5 (enExample) | 2013-07-11 |
| JP5829210B2 JP5829210B2 (ja) | 2015-12-09 |
Family
ID=42834367
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520789A Expired - Fee Related JP5829210B2 (ja) | 2009-07-15 | 2010-07-15 | Ｒｓｖｆタンパク質組成物およびそれを作製するための方法 |
| JP2015095502A Pending JP2015145422A (ja) | 2009-07-15 | 2015-05-08 | Ｒｓｖｆタンパク質組成物およびそれを作製するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095502A Pending JP2015145422A (ja) | 2009-07-15 | 2015-05-08 | Ｒｓｖｆタンパク質組成物およびそれを作製するための方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (13) | US20120164176A1 (enExample) |
| EP (6) | EP4218800A1 (enExample) |
| JP (2) | JP5829210B2 (enExample) |
| CN (2) | CN105214080A (enExample) |
| AR (1) | AR077757A1 (enExample) |
| BR (1) | BR112012001666A2 (enExample) |
| CA (1) | CA2768186A1 (enExample) |
| CL (1) | CL2012000119A1 (enExample) |
| CO (1) | CO6491045A2 (enExample) |
| DK (1) | DK3178490T3 (enExample) |
| ES (3) | ES2563730T3 (enExample) |
| HR (1) | HRP20220756T1 (enExample) |
| HU (1) | HUE058971T2 (enExample) |
| LT (1) | LT3178490T (enExample) |
| MX (1) | MX2012000667A (enExample) |
| PL (1) | PL3178490T3 (enExample) |
| PT (1) | PT3178490T (enExample) |
| RU (1) | RU2585227C2 (enExample) |
| SG (1) | SG178026A1 (enExample) |
| SI (1) | SI3178490T1 (enExample) |
| TW (1) | TW201116294A (enExample) |
| WO (1) | WO2011008974A2 (enExample) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| PT3067064T (pt) * | 2008-12-09 | 2020-06-16 | Novavax Inc | Proteínas f vsr modificadas e processos para a sua utilização |
| WO2011008974A2 (en) | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
| US9770463B2 (en) * | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| PT2590626E (pt) | 2010-07-06 | 2016-01-26 | Glaxosmithkline Biolog Sa | Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn |
| RS63817B1 (sr) * | 2010-07-06 | 2023-01-31 | Glaxosmithkline Biologicals Sa | Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| HUE058361T2 (hu) | 2010-08-31 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Pegilált liposzómák immunogént kódoló RNA bejuttatására |
| EP2611467B1 (en) | 2010-08-31 | 2022-07-20 | GlaxoSmithKline Biologicals SA | Small liposomes for delivery of immunogen-encoding rna |
| ES2945135T3 (es) | 2010-10-11 | 2023-06-28 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
| US10342862B2 (en) | 2011-01-26 | 2019-07-09 | Glaxosmithkline Biologicals, Sa | RSV immunization regimen |
| WO2012117045A1 (en) * | 2011-03-02 | 2012-09-07 | Intervet International B.V. | Infectious bronchitis virus (ibv) spike protein as subunit vaccine |
| EP2689016B1 (en) * | 2011-03-22 | 2015-03-11 | Mucosis B.V. | Immunogenic compositions in particulate form and methods for producing the same |
| WO2012129483A1 (en) * | 2011-03-24 | 2012-09-27 | Novartis Ag | Adjuvant nanoemulsions with phospholipids |
| PL3275892T3 (pl) * | 2011-05-13 | 2020-09-07 | Glaxosmithkline Biologicals S.A. | Przedfuzyjne antygeny RSV F |
| CN103906527B (zh) | 2011-06-08 | 2020-07-10 | 川斯勒佰尔公司 | Mrna递送的脂质纳米颗粒组合物和方法 |
| EP3336082B1 (en) | 2011-06-08 | 2020-04-15 | Translate Bio, Inc. | Cleavable lipids |
| CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| ES2861428T3 (es) | 2011-07-06 | 2021-10-06 | Glaxosmithkline Biologicals Sa | Liposomas que presentan una relación N:P útil para suministro de moléculas de ARN |
| JP2014525461A (ja) * | 2011-08-31 | 2014-09-29 | ノバルティス アーゲー | 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム |
| US9125870B2 (en) * | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| WO2013155205A1 (en) * | 2012-04-10 | 2013-10-17 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same |
| CN104540520B (zh) | 2012-08-01 | 2018-10-23 | 巴法里安诺迪克有限公司 | 重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗 |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
| EA201590683A1 (ru) | 2012-11-20 | 2015-11-30 | Глаксосмитклайн Байолоджикалс С.А. | Тримеры rsv f, предшествующие слиянию |
| RU2015132962A (ru) * | 2013-01-10 | 2017-02-14 | Новартис Аг | Иммуногенные композиции на основе вируса гриппа и их применение |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| PL2970398T3 (pl) | 2013-03-13 | 2024-09-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Białka f rsv przed fuzją i ich zastosowanie |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| US9060975B2 (en) * | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
| WO2014152534A1 (en) | 2013-03-14 | 2014-09-25 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| DE102013004595A1 (de) * | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
| HK1221641A1 (zh) * | 2013-04-08 | 2017-06-09 | Medimmune, Llc | 疫苗组合物及使用方法 |
| RS58436B1 (sr) * | 2013-04-25 | 2019-04-30 | Janssen Vaccines & Prevention Bv | Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi |
| CA2914792C (en) | 2013-06-17 | 2024-02-27 | Crucell Holland B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
| KR20160040290A (ko) | 2013-08-05 | 2016-04-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 조합 면역원성 조성물 |
| CA2915730A1 (en) * | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
| EP3270962A4 (en) * | 2015-03-17 | 2018-08-22 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US10456462B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Preventions B.V. | Vaccine against RSV |
| KR20180026734A (ko) | 2015-07-07 | 2018-03-13 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 융합-전 rsv f 폴리펩티드 |
| CA2996762A1 (en) * | 2015-08-31 | 2017-03-09 | Technovax, Inc. | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine |
| EP3344291B1 (en) | 2015-09-03 | 2024-11-27 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| EP3368547A4 (en) | 2015-10-29 | 2019-06-05 | Emory University | CHIMERIC RSV, IMMUNOGENIC COMPOSITIONS AND METHOD FOR USE THEREOF |
| PE20232039A1 (es) | 2015-12-23 | 2023-12-21 | Pfizer | Mutantes de proteina f de rsv |
| CN115960263A (zh) * | 2016-03-29 | 2023-04-14 | 美国政府(由卫生和人类服务部的部长所代表) | 取代修饰的融合前rsv f蛋白及其用途 |
| SMT202100106T1 (it) | 2016-04-05 | 2021-03-15 | Janssen Vaccines & Prevention Bv | Proteina f di rsv pre-fusione solubile stabilizzata per uso nella profilassi di infezione da rsv |
| MX2018012095A (es) | 2016-04-05 | 2019-01-10 | Janssen Vaccines & Prevention Bv | Vacuna contra vrs. |
| CN106124767A (zh) * | 2016-05-12 | 2016-11-16 | 广州瑞辉生物科技股份有限公司 | 呼吸道合胞病毒IgA抗体检测试纸条及其检测方法 |
| EA039124B1 (ru) | 2016-05-30 | 2021-12-08 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные f-белки rsv до слияния |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| TWI634899B (zh) * | 2016-11-22 | 2018-09-11 | 國立臺灣大學 | 包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| PL3601367T3 (pl) | 2017-03-30 | 2025-03-31 | The University Of Queensland | Cząsteczki chimeryczne i ich zastosowania |
| US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| JP7291633B2 (ja) | 2017-05-30 | 2023-06-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アジュバントを製造する方法 |
| CN111148509A (zh) | 2017-07-24 | 2020-05-12 | 诺瓦瓦克斯股份有限公司 | 治疗呼吸系统疾病的方法和组合物 |
| CA3071011A1 (en) * | 2017-07-28 | 2019-01-31 | Janssen Vaccines & Prevention B.V. | Methods and compositions for heterologous reprna immunizations |
| AU2018313000B2 (en) | 2017-08-07 | 2025-07-03 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| CN111163800A (zh) | 2017-09-15 | 2020-05-15 | 扬森疫苗与预防公司 | 用于安全诱导针对rsv的免疫的方法 |
| BR112020010790A2 (pt) | 2017-12-01 | 2020-11-10 | Glaxosmithkline Biologicals S.A. | purificação da saponina |
| WO2019147749A2 (en) | 2018-01-29 | 2019-08-01 | Merck Sharp & Dohme Corp. | Stabilized rsv f proteins and uses thereof |
| SG11202009206QA (en) | 2018-03-19 | 2020-10-29 | Novavax Inc | Multivalent influenza nanoparticle vaccines |
| WO2019191623A1 (en) * | 2018-03-30 | 2019-10-03 | Georgia State University Research Foundation, Inc. | Respiratory syncytial virus (rsv) vaccines |
| MX2020010199A (es) | 2018-04-03 | 2021-01-08 | Sanofi Sa | Polipeptidos antigenicos del virus sincitial respiratorio. |
| JP2021533162A (ja) | 2018-08-07 | 2021-12-02 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | プロセス及びワクチン |
| KR102725189B1 (ko) * | 2018-11-01 | 2024-10-31 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
| BR112021008975A2 (pt) | 2018-11-13 | 2021-08-17 | Janssen Vaccines & Prevention B.V. | proteínas f do rsv pré-fusão estabilizadas |
| CN109694400A (zh) * | 2019-01-31 | 2019-04-30 | 苏州高泓利康生物科技有限公司 | 一种表达呼吸道合胞病毒f蛋白及其制备方法 |
| EP3956351A1 (en) * | 2019-04-18 | 2022-02-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Biological and synthetic molecules inhibiting respiratory syncytial virus infection |
| CA3142300C (en) | 2019-06-05 | 2025-02-04 | Glaxosmithkline Biologicals Sa | SAPONIN PURIFICATION |
| US20230054711A1 (en) * | 2019-12-31 | 2023-02-23 | Xiamen University | Multimerization delivery system for intracellular delivery of molecule |
| US20230348880A1 (en) * | 2020-02-27 | 2023-11-02 | National Institute Of Biological Sciences, Beijing | Soluble ace2 and fusion protein, and applications thereof |
| WO2021249009A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Rsv vaccine compositions, methods, and uses thereof |
| IL299787A (en) | 2020-07-16 | 2023-03-01 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| CN114685676B (zh) * | 2020-12-28 | 2024-02-13 | 兰州生物制品研究所有限责任公司 | 一种重组蛋白及其表达方法、纯化方法及用途 |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| CN118647600A (zh) | 2021-12-16 | 2024-09-13 | 爱康泰生治疗公司 | 用于脂质纳米颗粒制剂的脂质 |
| EP4536274A1 (en) * | 2022-06-10 | 2025-04-16 | GlaxoSmithKline Biologicals SA | Rsv vaccination with trimeric rsv f fusion protein |
| JP2025532724A (ja) | 2022-09-29 | 2025-10-03 | ファイザー・インク | Ｒｓｖ ｆタンパク質三量体を含む免疫原性組成物 |
| WO2024078597A1 (en) * | 2022-10-13 | 2024-04-18 | Rvac Medicines (Us) , Inc. | Rsv f protein variants and uses thereof |
| EP4608441A1 (en) | 2022-10-27 | 2025-09-03 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| EP4608440A1 (en) | 2022-10-27 | 2025-09-03 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
| CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
| WO2024127181A1 (en) | 2022-12-11 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| EP4652184A2 (en) * | 2023-01-17 | 2025-11-26 | The Scripps Research Institute | Engineered paramyxovirus soluble fusion (f) proteins and related vaccines |
| AU2024209772A1 (en) | 2023-01-18 | 2025-06-26 | Pfizer Inc. | Vaccines against respiratory diseases |
| AU2024224721A1 (en) * | 2023-02-21 | 2025-10-09 | Msd International Business Gmbh | Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain |
| WO2024194153A1 (en) * | 2023-03-17 | 2024-09-26 | Glaxosmithkline Biologicals Sa | Rsv-f-encoding nucleic acids |
| CN118994328B (zh) * | 2023-05-19 | 2025-07-08 | 珠海丽凡达生物技术有限公司 | 呼吸道合胞病毒疫苗及其制备方法和应用 |
| TW202515531A (zh) | 2023-07-07 | 2025-04-16 | 美商輝瑞股份有限公司 | 兩親性ｔｌｒ７／８佐劑及其用途 |
| CN119490569A (zh) * | 2023-08-16 | 2025-02-21 | 深圳瑞吉生物科技有限公司 | 呼吸道合胞病毒抗原性多肽、核酸、疫苗及其应用 |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| EP4520334A1 (en) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025059498A2 (en) * | 2023-09-15 | 2025-03-20 | Icosavax, Inc. | Viral proteins and nanostructures and uses thereof |
| AR133818A1 (es) * | 2023-09-15 | 2025-11-05 | Icosavax Inc | Proteínas f y nanoestructuras del virus respiratorio sincitial y usos de estas |
| CN117304280B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
| CN117304278B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025147496A1 (en) * | 2024-01-03 | 2025-07-10 | Curevo, Inc. | Combination vaccines and methods of use |
| WO2025149032A1 (en) * | 2024-01-11 | 2025-07-17 | Immorna (hangzhou) Biotechnology Co., Ltd. | Respiratory syncytial virus vaccine compositions and their use |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025186719A1 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (175)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US119A (en) | 1837-02-10 | Improvement in the machine for weighing heavy bodies | ||
| US139A (en) | 1837-03-11 | Robert wilson | ||
| US118A (en) | 1837-02-10 | Improvement in the machine for weighing heavy bodies | ||
| US4186745A (en) | 1976-07-30 | 1980-02-05 | Kauzlarich James J | Porous catheters |
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
| US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| US5639853A (en) | 1987-09-29 | 1997-06-17 | Praxis Biologics, Inc. | Respiratory syncytial virus vaccines |
| ATE85622T1 (de) | 1987-12-23 | 1993-02-15 | Upjohn Co | Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus. |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| AU625013B2 (en) | 1989-11-03 | 1992-06-25 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| ES2186034T3 (es) | 1991-03-01 | 2003-05-01 | Minnesota Mining & Mfg | Intermedios para la preparacion de 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas, 2-sustituidas. |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| ATE156710T1 (de) | 1992-06-25 | 1997-08-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| CA2151597A1 (en) | 1993-01-08 | 1994-07-21 | Robert L. Garlick | Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| NZ263538A (en) | 1993-03-23 | 1996-10-28 | Smithkline Beecham Biolog | Vaccine compositions of 3-o-deacylated monophosphoryl lipid a |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| CZ288182B6 (en) | 1993-07-15 | 2001-05-16 | Minnesota Mining & Mfg | Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| US6005099A (en) | 1993-11-17 | 1999-12-21 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
| US5397307A (en) | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| JP3403233B2 (ja) | 1994-01-20 | 2003-05-06 | テルモ株式会社 | バルーンカテーテル |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
| ATE502651T1 (de) | 1994-11-17 | 2011-04-15 | Ich Productions Ltd | Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| GB9503863D0 (en) | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| CA2283557A1 (en) | 1997-03-10 | 1998-09-17 | Heather L. Davis | Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
| US6090619A (en) | 1997-09-08 | 2000-07-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
| CN1259422C (zh) | 1997-09-19 | 2006-06-14 | 惠氏控股有限公司 | 呼吸合胞病毒的吸附(g)蛋白衍生的肽 |
| AU9676198A (en) | 1997-10-01 | 1999-04-23 | C.R. Bard Inc. | Drug delivery and gene therapy delivery system |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| AU746163B2 (en) | 1998-04-09 | 2002-04-18 | Smithkline Beecham Biologicals (Sa) | Adjuvant compositions |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| SK18602000A3 (sk) | 1998-06-08 | 2001-07-10 | Sca Emballage France | Obal umožňujúci rýchle vyrovnanie |
| DE69935330T2 (de) | 1998-06-30 | 2007-10-31 | Om Pharma | Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| EP1797896A1 (en) | 1998-10-16 | 2007-06-20 | GlaxoSmithKline Biologicals SA | Adjuvant systems and vaccines |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| DK1150918T3 (da) | 1999-02-03 | 2004-12-20 | Biosante Pharmaceuticals Inc | Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler |
| ATE549032T1 (de) | 1999-03-26 | 2012-03-15 | Vical Inc | Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| JP2003509473A (ja) | 1999-09-24 | 2003-03-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
| AR025749A1 (es) | 1999-09-24 | 2002-12-11 | Smithkline Beecham Biolog | Vacunas |
| AU780979B2 (en) | 1999-09-25 | 2005-04-28 | Coley Pharmaceutical Gmbh | Immunostimulatory nucleic acids |
| WO2001046127A1 (fr) | 1999-12-22 | 2001-06-28 | Om Pharma | Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise |
| WO2001095935A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
| ES2334641T3 (es) | 2000-09-01 | 2010-03-15 | Novartis Vaccines And Diagnostics, Inc. | Derivados aza heterociclicos y su uso terapeutico. |
| ES2250480T3 (es) | 2000-09-11 | 2006-04-16 | Chiron Corporation | Derivados de quinolinona como inhibidores de tirosina quinasa. |
| KR100894767B1 (ko) | 2000-09-26 | 2009-04-24 | 이데라 파마슈티칼즈, 인코포레이티드 | 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법 |
| AU2002223275A1 (en) | 2000-11-22 | 2002-06-03 | Biota Scientific Management Pty Ltd | A method of expression and agents identified thereby |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| WO2002074969A2 (en) | 2001-01-26 | 2002-09-26 | University Of Lausanne | Matrix attachment regions and methods for use thereof |
| EP1372706B1 (en) | 2001-03-09 | 2010-12-01 | ID Biomedical Corporation of Quebec | Proteosome-liposaccharide vaccine adjuvant |
| DE60228229D1 (de) | 2001-04-17 | 2008-09-25 | Dainippon Sumitomo Pharma Co | Neue adeninderivate |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| AU2002343728A1 (en) | 2001-11-16 | 2003-06-10 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor pathways |
| FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
| NZ533628A (en) | 2001-11-27 | 2006-07-28 | Anadys Pharmaceuticals Inc | 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof |
| US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| TWI344991B (en) | 2002-02-21 | 2011-07-11 | Medimmune Vaccines Inc | Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| MXPA04009541A (es) | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
| WO2003083095A1 (en) * | 2002-04-03 | 2003-10-09 | Akzo Nobel N.V. | Viral mutants, manipulated in the furin cleavage sites of glycoproteins |
| JP2005531599A (ja) | 2002-05-29 | 2005-10-20 | スリーエム イノベイティブ プロパティズ カンパニー | イミダゾ［４，５−ｃ］ピリジン−４−アミンのための方法 |
| EP1551228B1 (en) | 2002-06-13 | 2012-10-03 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| KR20050038631A (ko) | 2002-08-23 | 2005-04-27 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 피롤 기제 억제제 |
| PT2311848E (pt) | 2002-12-23 | 2013-10-03 | Vical Inc | Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano |
| EP1587473A4 (en) | 2002-12-27 | 2008-08-13 | Novartis Vaccines & Diagnostic | THIOSEMICARBAZONE AS VIRUZIDES AND IMMUNOSTIMULATORS |
| US8193185B2 (en) | 2003-01-21 | 2012-06-05 | Novartis Vaccines And Diagnostics, Inc. | Use of tryptanthrin compounds for immune potentiation |
| GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| WO2004071459A2 (en) | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
| US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
| US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| US8252917B2 (en) | 2003-10-24 | 2012-08-28 | Selexis S.A. | High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of MAR sequences |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| EP1732384A4 (en) | 2004-03-31 | 2008-04-23 | Univ New York State Res Found | NOVEL SYNTHETIC C-GLYCOLIPIDES, THEIR SYNTHESIS AND USE FOR THE TREATMENT OF INFECTIONS, CANCER AND AUTOIMMUNE DISEASES |
| ES2409782T3 (es) | 2004-04-05 | 2013-06-27 | Zoetis P Llc | Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna |
| CA2566355C (en) | 2004-05-18 | 2014-04-15 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
| WO2006011060A2 (en) | 2004-07-23 | 2006-02-02 | Chiron Srl | Polypeptides for oligomeric assembly of antigens |
| FR2873378A1 (fr) | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques |
| WO2006042156A2 (en) | 2004-10-08 | 2006-04-20 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS represneted by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION | Modulation of replicative fitness by using less frequently used synonymous codons |
| GB0422439D0 (en) | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| WO2008061243A2 (en) * | 2006-11-16 | 2008-05-22 | Novavax, Inc. | Respiratory syncytial virus-virus like particle (vlps) |
| EP2181121A4 (en) * | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
| WO2008154456A2 (en) * | 2007-06-06 | 2008-12-18 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
| CN101148479A (zh) * | 2007-09-11 | 2008-03-26 | 浙江理工大学 | 一种重组类人胶原蛋白及生物合成方法 |
| US8563002B2 (en) | 2007-12-24 | 2013-10-22 | Glaxosmithkline Biologicals, S.A. | Recombinant RSV antigens |
| ES2546213T3 (es) | 2008-03-03 | 2015-09-21 | Novartis Ag | Compuestos y composiciones como moduladores de la actividad de TLR |
| WO2009128949A2 (en) | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Compositions of dengue viral proteins and methods of use |
| WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
| WO2010009277A2 (en) * | 2008-07-15 | 2010-01-21 | Novartis Ag | Immunogenic amphipathic peptide compositions |
| CN102131830A (zh) | 2008-07-18 | 2011-07-20 | 魁北克益得生物医学公司 | 嵌合呼吸道合胞病毒多肽抗原 |
| PT3067064T (pt) * | 2008-12-09 | 2020-06-16 | Novavax Inc | Proteínas f vsr modificadas e processos para a sua utilização |
| WO2010077712A1 (en) | 2008-12-09 | 2010-07-08 | Novavax, Inc. | Bovine respiratory syncytial virus virus-like particle (vlps) |
| EA023054B1 (ru) | 2009-06-24 | 2016-04-29 | Глэксосмитклайн Байолоджикалз С.А. | Рекомбинантные антигены pcb |
| SG176807A1 (en) | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
| WO2011008974A2 (en) * | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| EP2689016B1 (en) | 2011-03-22 | 2015-03-11 | Mucosis B.V. | Immunogenic compositions in particulate form and methods for producing the same |
| PL3275892T3 (pl) | 2011-05-13 | 2020-09-07 | Glaxosmithkline Biologicals S.A. | Przedfuzyjne antygeny RSV F |
| ES2395677B1 (es) | 2011-07-29 | 2013-12-26 | Instituto De Salud Carlos Iii | Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma. |
| US10202616B2 (en) | 2014-10-15 | 2019-02-12 | Amgen Inc. | Promoter and regulatory elements for improved expression of heterologous genes in host cells |
| PL3601367T3 (pl) | 2017-03-30 | 2025-03-31 | The University Of Queensland | Cząsteczki chimeryczne i ich zastosowania |
-
2010
- 2010-07-15 WO PCT/US2010/042161 patent/WO2011008974A2/en not_active Ceased
- 2010-07-15 RU RU2012105308/10A patent/RU2585227C2/ru not_active IP Right Cessation
- 2010-07-15 ES ES10734875.7T patent/ES2563730T3/es active Active
- 2010-07-15 DK DK16190004.8T patent/DK3178490T3/da active
- 2010-07-15 ES ES16190004T patent/ES2918381T3/es active Active
- 2010-07-15 CN CN201510703646.0A patent/CN105214080A/zh active Pending
- 2010-07-15 LT LTEP16190004.8T patent/LT3178490T/lt unknown
- 2010-07-15 EP EP22214608.6A patent/EP4218800A1/en active Pending
- 2010-07-15 EP EP21199223.5A patent/EP3988115A3/en not_active Withdrawn
- 2010-07-15 TW TW099123300A patent/TW201116294A/zh unknown
- 2010-07-15 EP EP10734875.7A patent/EP2453918B1/en active Active
- 2010-07-15 HU HUE16190004A patent/HUE058971T2/hu unknown
- 2010-07-15 JP JP2012520789A patent/JP5829210B2/ja not_active Expired - Fee Related
- 2010-07-15 EP EP22200670.2A patent/EP4183412B1/en active Active
- 2010-07-15 CN CN201080040594.9A patent/CN102639147B/zh not_active Expired - Fee Related
- 2010-07-15 MX MX2012000667A patent/MX2012000667A/es active IP Right Grant
- 2010-07-15 US US13/383,897 patent/US20120164176A1/en not_active Abandoned
- 2010-07-15 ES ES22200670T patent/ES2991844T3/es active Active
- 2010-07-15 SG SG2012002481A patent/SG178026A1/en unknown
- 2010-07-15 EP EP22214601.1A patent/EP4218799A1/en active Pending
- 2010-07-15 HR HRP20220756TT patent/HRP20220756T1/hr unknown
- 2010-07-15 BR BR112012001666A patent/BR112012001666A2/pt not_active IP Right Cessation
- 2010-07-15 AR ARP100102599A patent/AR077757A1/es unknown
- 2010-07-15 EP EP16190004.8A patent/EP3178490B1/en active Active
- 2010-07-15 CA CA2768186A patent/CA2768186A1/en not_active Abandoned
- 2010-07-15 SI SI201032111T patent/SI3178490T1/sl unknown
- 2010-07-15 PT PT161900048T patent/PT3178490T/pt unknown
- 2010-07-15 US US12/836,931 patent/US20110305727A1/en not_active Abandoned
- 2010-07-15 PL PL16190004.8T patent/PL3178490T3/pl unknown
-
2012
- 2012-01-13 CL CL2012000119A patent/CL2012000119A1/es unknown
- 2012-01-17 CO CO12006115A patent/CO6491045A2/es unknown
-
2015
- 2015-05-08 JP JP2015095502A patent/JP2015145422A/ja active Pending
-
2017
- 2017-08-16 US US15/678,798 patent/US11261239B2/en active Active
-
2021
- 2021-12-29 US US17/564,962 patent/US11820812B2/en active Active
-
2022
- 2022-06-23 US US17/848,176 patent/US11629181B2/en active Active
- 2022-06-23 US US17/848,205 patent/US11655284B2/en active Active
-
2023
- 2023-02-22 US US18/173,006 patent/US11827694B2/en active Active
- 2023-05-24 US US18/323,177 patent/US20230357369A1/en not_active Abandoned
- 2023-05-24 US US18/323,185 patent/US20230357370A1/en not_active Abandoned
- 2023-05-24 US US18/323,166 patent/US20240034773A1/en not_active Abandoned
- 2023-05-24 US US18/323,215 patent/US20230303669A1/en not_active Abandoned
- 2023-05-24 US US18/323,209 patent/US20230348575A1/en not_active Abandoned
- 2023-05-24 US US18/323,192 patent/US20230357371A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012533558A5 (enExample) | ||
| US12234264B2 (en) | Stabilized soluble pre-fusion RSV F proteins | |
| US10953087B2 (en) | Stabilized pre-fusion RSV F proteins | |
| WO2012089231A1 (en) | Paramyxovirus vaccines | |
| AU2013349778A1 (en) | RSV F prefusion trimers | |
| JP2009534024A (ja) | パラミクソウイルス科（Ｐａｒａｍｙｘｏｖｉｒｉｄａｅ）ファミリーのウイルスのＮタンパク質−対象タンパク質の融合タンパク質 | |
| US20240189416A1 (en) | Stabilized coronavirus spike protein fusion proteins | |
| US12370252B2 (en) | RSV virus-like particles and methods of use thereof | |
| US9896484B2 (en) | Influenza virus recombinant proteins | |
| EP4568699A2 (en) | Rabies g protein and uses thereof | |
| HK40051597A (en) | Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection | |
| HK1261073A1 (en) | Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection | |
| HK1261073B (en) | Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection | |
| OA19273A (en) | Stabilized pre-fusion RSV F proteins. | |
| OA18879A (en) | Stabilized soluble pre-fusion RSV F proteins | |
| NZ785677A (en) | Stabilized soluble pre-fusion rsv f proteins | |
| HK40000138B (en) | Stabilized pre-fusion rsv f proteins | |
| HK40000138A (en) | Stabilized pre-fusion rsv f proteins |